These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35625962)

  • 1. Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review.
    Falette Puisieux M; Pellat A; Assaf A; Ginestet C; Brezault C; Dhooge M; Soyer P; Coriat R
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
    Dipasquale A; Marinello A; Santoro A
    J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A concise review of the changing landscape of hepatocellular carcinoma.
    Draper A
    Am J Manag Care; 2020 Oct; 26(10 Suppl):S211-S219. PubMed ID: 33052638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
    Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).
    Ghaziani TT; Dhanasekaran R
    Curr Treat Options Gastroenterol; 2021 Jun; 19(2):351-368. PubMed ID: 35530750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
    Ponvilawan B; Roth MT
    Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.
    Alqahtani SA; Colombo MG
    World J Gastrointest Oncol; 2021 Dec; 13(12):2038-2049. PubMed ID: 35070040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.
    Yoo C; Kim JH; Ryu MH; Park SR; Lee D; Kim KM; Shim JH; Lim YS; Lee HC; Lee J; Tai D; Chan SL; Ryoo BY
    Liver Cancer; 2021 Apr; 10(2):107-114. PubMed ID: 33977087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
    Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
    J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma.
    Rehman O; Jaferi U; Padda I; Khehra N; Atwal H; Mossabeh D; Bhangu R
    Clin Exp Hepatol; 2021 Sep; 7(3):249-257. PubMed ID: 34712825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.